Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,650 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,128 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,492)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05416775 | Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 168 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05507593 | Study of DLL3-CAR-NK Cells in the Treatment of Extensive Stage Small Cell Lung Cancer | unknown | Phase 1 | 18 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 19, 2022 |
| clinicaltrials |
| NCT05507606 | Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations | unknown | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT04122833 | Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study | unknown | — | 80 | Konkuk University Medical CenterOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05380024 | A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer | unknown | Phase 2 | 10 | Peking University Cancer Hospital & InstituteOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04749394 | A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy | unknown | Phase 2 | 42 | Chinese Academy of Medical SciencesOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT03934827 | MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour(MICROBIOME) | unknown | Phase 1 | 120 | Imperial College LondonOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05497544 | ORE - 30 Seconds (Oncologists Recommend Exercise in 30 Secs)(ORE) | unknown | N/A | 60 | Universita di VeronaOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05332574 | A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor | unknown | Phase 1 / Phase 2 | 120 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Aug 5, 2022 | clinicaltrials |
| NCT05117658 | Study of HA121-28 in Patients With Non-Small Cell Lung Cancer | unknown | Phase 2 | 83 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05255406 | Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE) | unknown | Phase 2 | 62 | Fudan UniversityOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05486988 | ctDNA as a Biomarker for Treatment in Advanced NSCLC | unknown | — | 500 | Fuzhou General HospitalOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05136300 | Pulmonary Rehabilitation After Minimal Invasive Surgery in Lung Cancer(PROMISE) | unknown | N/A | 100 | IsalaOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT05485350 | Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 32 | Peking University Third HospitalOTHER | 0 | Aug 3, 2022 | clinicaltrials |
| NCT05483543 | Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy | unknown | Phase 2 | 44 | Fudan UniversityOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05430009 | Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer | unknown | Phase 1 | 12 | VA Ann Arbor Healthcare SystemFED | 1 | Aug 1, 2022 | clinicaltrials |
| NCT05482087 | A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC | unknown | Phase 2 | 190 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 1, 2022 | clinicaltrials |
| NCT04197076 | Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB | unknown | — | 200 | Shanghai Chest HospitalOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT04366219 | Impact of Confinement and Preventive Measures in Period of SARS-COV2 Infection on Clinical Features, Diagnostic and Therapeutic Management and Prognosis of Patients With Lung Cancer(CBP-COVID) | unknown | — | 2,000 | Centre Hospitalier le MansOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT05477615 | Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases | unknown | Phase 2 | 28 | Jin Hyoung KangOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT05453812 | Meaning of Recovery After Lung Cancer Surgery | unknown | — | 111 | Seoul National University HospitalOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT03971175 | Influence of Biopsy Technique on Moleculargenetic Tumor Characterisation in NSCLC(PROFILER) | unknown | N/A | 540 | University Hospital TuebingenOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT05068024 | A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer(FWD1509) | unknown | Phase 1 / Phase 2 | 30 | Forward Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 26, 2022 | clinicaltrials |
| NCT05458726 | Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC | unknown | Phase 2 | 80 | Peking Union Medical CollegeOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT05472350 | Efficacy and Safety of Perioperative Use of Breztri Aerosphere to Relieve Cough After Lobectomy | unknown | N/A | 128 | Jianxing HeOTHER | 0 | Jul 25, 2022 | clinicaltrials |
| NCT05472467 | Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer(IMCORT-2) | unknown | Phase 2 | 35 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT05468294 | F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer(Nivokin) | unknown | Phase 1 / Phase 2 | 3 | Philogen S.p.A.INDUSTRY | 1 | Jul 21, 2022 | clinicaltrials |
| NCT05460481 | Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors | unknown | Phase 2 | 29 | Hunan Cancer HospitalOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT04957433 | 'Lung Health Check' Biomarker Study | unknown | — | 1,000 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jul 18, 2022 | clinicaltrials |
| NCT05460195 | Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation | unknown | Phase 2 | 42 | Shanghai Chest HospitalOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT05273814 | Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer | unknown | Phase 1 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 13, 2022 | clinicaltrials |
| NCT04459611 | Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）(neoSCORE) | unknown | Phase 2 | 60 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 12, 2022 | clinicaltrials |
| NCT05451056 | An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib(breakthrough) | unknown | Phase 2 | 37 | Yonsei UniversityOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT05448781 | Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC | unknown | Phase 2 | 38 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Jul 7, 2022 | clinicaltrials |
| NCT05027100 | Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC | unknown | N/A | 33 | Haibo ZhangOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT05400304 | Radiomics Combined With Frozen Section Prediction Model for Spread Through Air Space in Lung Adenocarcinoma | unknown | — | 900 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Jun 29, 2022 | clinicaltrials |
| NCT05435274 | Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 380 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 28, 2022 | clinicaltrials |
| NCT05431569 | A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer | unknown | Phase 2 | 36 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 0 | Jun 24, 2022 | clinicaltrials |
| NCT05426317 | Exploratory Interventional Study of Prognostic Serum Biomarkers of Cancer Progression(Onco-PDL1s/B2M) | unknown | N/A | 100 | University Hospital, Clermont-FerrandOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT05369312 | Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients | unknown | Phase 1 | 230 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT05423236 | Clinical Characteristics of Lung Cancer in China | unknown | — | 119,785 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT05417672 | Assessment of Relationship Between Preoperative Nutritional Status and Perioperative/Postoperative Conditions in Patients With Lung Cancer Scheduled for Lobectomy | unknown | — | 63 | Turkish Society of Anesthesiology and ReanimationOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT05414630 | A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer | unknown | Phase 2 | 30 | Anhui Provincial Cancer HospitalOTHER | 1 | Jun 10, 2022 | clinicaltrials |
| NCT05411276 | A Real-World Study of Pyrotinib Maleate in the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer With Rare Mutations in HER2 | unknown | — | 15 | Beijing Chest HospitalOTHER | 0 | Jun 9, 2022 | clinicaltrials |
| NCT05331391 | A Mobile SMART Exercise Support Program to Improve Fatigue in Lung Cancer Patients - A RCT | unknown | N/A | 120 | The University of Hong KongOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT05394233 | Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC | unknown | Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT05395611 | Exhaled Breath Particles in Lung Cancer | unknown | — | 300 | Lund University HospitalOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT04029155 | Conventional vs Ultrathin Bronchoscopy for Peripheral Pulmonary Lesions | unknown | N/A | 142 | Stefano GaspariniOTHER | 0 | May 26, 2022 | clinicaltrials |
| NCT05392686 | PD1 and PARP for Maintenance Therapy in NSLLC | unknown | Phase 2 | 52 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 26, 2022 | clinicaltrials |
| NCT05387044 | SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors | unknown | Phase 2 | 28 | Zhejiang Cancer HospitalOTHER | 1 | May 24, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Aug 19, 2022source: clinicaltrials